Efficacy and safety of Huanglong Zhike Granules as adjunctive therapy for asthma: a systematic review and meta-analysis
Frontiers in Medicine · 19.11.2026 · 13
DOI: 10.3389/fmed.2026.2005189 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Medicine, online erschienen am 19.11.2026. Verfasst von Yuning Shen und 5 weiteren Autor:innen. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Bronchial asthma is a heterogeneous airway disease mainly characterized by chronic airway inflammation. Huanglong Zhike Granules are used alongside conventional therapy for asthma, particularly cough variant asthma, but their overall efficacy and safety remain uncertain. This review evaluated the efficacy and safety of Huanglong Zhike Granules as adjunctive treatment for asthma.
Methods
Seven databases were searched from inception to 27 October 2026. Study selection and data extraction were performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. Meta-analyses were conducted using RevMan 5.4 and Stata 17.0. Subgroup and sensitivity analyses were performed where appropriate. Small-study effects were explored for outcomes with at least 10 contributing studies. The certainty of evidence for the primary and secondary outcomes was assessed using the GRADE approach.
Results
A total of 17 RCTs involving 1,583 patients were included. Adjunctive Huanglong Zhike Granules improved FEV 1 (MD = 0.29 L, 95% CI 0.19–0.38), FVC (MD = 0.29 L, 95% CI 0.16–0.42), FEV 1 /FVC (MD = 6.07 percentage points, 95% CI 3.92–8.22), PEF (SMD = 1.13, 95% CI 0.82–1.44), and overall response rate (RR = 1.20, 95% CI 1.15–1.25). Improvements were also observed in several inflammatory and airway remodeling-related indicators. Pooled ACT scores showed no significant difference, whereas the single C-ACT study favored combination therapy. No significant difference in adverse events was detected (RR = 0.89, 95% CI 0.52–1.51), although safety data were limited. The certainty of evidence for all five primary outcomes was low.
Conclusion
Huanglong Zhike Granules added to conventional Western therapy may improve pulmonary function and several inflammation- and airway remodeling-related outcomes in patients with asthma. However, these findings should be interpreted cautiously because of methodological limitations, substantial heterogeneity in several outcomes, and evidence of very low to low certainty. Available short-term data showed no statistically significant difference in reported adverse events between the two groups, but the imprecision of the estimate, incomplete reporting, and limited follow-up do not establish equivalent or long-term safety. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD420261488793 , PROSPERO CRD420261488793.
Zitieren
APA
Shen, Y., Li, J., Liu, B., Gao, W., Yao, J., & Geng, L. (2026). Efficacy and safety of Huanglong Zhike Granules as adjunctive therapy for asthma: a systematic review and meta-analysis. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.2005189
Vancouver
Shen Y, Li J, Liu B, Gao W, Yao J, Geng L. Efficacy and safety of Huanglong Zhike Granules as adjunctive therapy for asthma: a systematic review and meta-analysis. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.2005189
BibTeX
@article{Shen2026,
author = {Shen, Yuning and Li, Jiaxiang and Liu, Baijun and Gao, Weihao and Yao, Jiayang and Geng, Limei},
title = {Efficacy and safety of Huanglong Zhike Granules as adjunctive therapy for asthma: a systematic review and meta-analysis},
journal = {Frontiers in Medicine},
year = {2026},
volume = {13},
doi = {10.3389/fmed.2026.2005189}
}
EUVIMED